НовостиBenzingaOS Therapies Initiates CMAA Process With UK MHRA For Herlystic In Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma; Expects To Complete CMAA Process Later In Q4 Of 2026 OS Therapies Initiates CMAA Process With UK MHRA For Herlystic In Prevention Or Delay Of Recurrence In Fully Resected, Pulmonary Metastatic Osteosarcoma; Expects To Complete CMAA Process Later In Q4 Of 2026 Benzinga 2026.11.10 13:19 (GMT+0) Открыть на Benzinga Другие новости